Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 Festival …Read More >

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the largest and longest-standing cancer research conferences in the world, will be held in Chicago. At this year’s AACR meeting, WuXi Biology has been selected to present several posters detailing latest scientific insights, covering a range …Read More >

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present multiple posters detailing latest scientific insights, covering a range of cutting-edge topics from preclinical tumor model development and biomarker discovery, to the evaluation of novel anti-cancer therapies. Explore this quick overview of WuXi Biology’s pioneering …Read More >

Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like olaparib targeting BRCA-deficient cells by exploiting this interaction.  Werner syndrome helicase (WRN) is a synthetic lethal target in cancers with microsatellite instability due to impaired DNA mismatch repair.  WRN is synthetically lethal with MLH1, a …Read More >

Polycythemia vera (PV) is a chronic myeloproliferative disorder, a type of blood cancer characterized by the overproduction of red blood cells (erythrocytosis) which can lead to thicker blood and an increased risk of blood clot.  Most cases of PV are caused by a point mutation in the JAK2 gene (JAK2-V617F). To support drug discovery teams …Read More >

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors to evade the immune system. IDO1 can also suppress the immune response through mechanisms independent of its enzyme activity, and this may be difficult to target with current inhibitors.  Drugs targeting only IDO1 enzyme activity …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical need. Although not fully understood, the mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce …Read More >

Women’s health care is crucial not only for the well-being of individual women but also for the health and prosperity of families and communities. Despite significant medical advancements, there remains a concerning gap in the availability of effective drugs for common women-related diseases such as endometriosis, menopause syndromes, polycystic ovary syndrome (PCOS), and various forms …Read More >

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset of patients remains refractory to ADC treatment.  WuXi AppTec contributed to a research article which demonstrated that excessive cancer-associated fibroblasts (CAFs) can form a fibrotic barrier within a tumor microenvironment, impeding the tissue uptake of …Read More >